Luis Costa

Employment

Employment history is unavailable.

Education

Education history is unavailable.

Projects & Funding

• Multifunctional nano-immunotherapy for melanoma brain metastases treatment Fundação para a Ciência e a Tecnologia
  2022 - 2025
• Physiopathology and clinical implications of the RANK c.1386C>T R450W mutation in breast cancer patients Fundação para a Ciência e a Tecnologia
  2018 - 2021
• Inervação patológica em metástases ósseas: OSTEOCLASTOS, o que estão a fazer? Fundação para a Ciência e a Tecnologia
  2018 - 2021
• Promoção do avanço significativo do conhecimento na área de medicina de precisão e sua translação para benefício da sociedade Fundação para a Ciência e a Tecnologia
  2016 - 2020
• The prognostic role of RANK SNP rs34945627 in breast cancer patients N/A
  2016 - 2017
• PERSEIDS - Personalizing cancer therapy through integrated modeling and decision N/A
  2016 - 2019
• ReTuBi: Towards outstanding research and training in tumour N/A
  2016 - 2018
• IMM Bridge Grant 2015 Fundação para a Ciência e a Tecnologia
  2015 - 2016
• Relative effectivity of aromatase inhibitors versus tamoxifen in patients with early breast cancer Fundação para a Ciência e a Tecnologia
  2014 - 2016
• CancerSys - Modelação multiscala para a terapia personalizada de metástases ósseas Fundação para a Ciência e a Tecnologia
  2014 - 2015
• Mechanisms and relevance of Phospholipase C epsilon downregulation in cancer Fundação para a Ciência e a Tecnologia
  2014 - 2015
• Sistemas Moleculares e Nano para Teranóstica de Cancro Fundação para a Ciência e a Tecnologia
  2013 - 2016
• Metal-based Multimodal Probes for Breast Cancer Imaging Targeting Y1-NPY Receptors: Synthesis, Characterization and Pre-clinical Evaluation N/A
  2013 - 2015
• Long Term Bisphosphonates N/A
  2012 - 2013
• Mechanisms of invasion and progression in metastatic bone disease and outcomes in HER2 positive metastatic breast cancer N/A
  2011 - 2014
• Molecular markers in multiple myeloma N/A
  2011 - 2015
• Oncobiologia: novas ferramentas educativas para as futuras gerações de investigadores clínicos Fundação para a Ciência e a Tecnologia
  2011 - 2014
• Assinaturas Moleculares de Prognóstico em Cancro Colorectal (AMPCC) Fundação para a Ciência e a Tecnologia
  2009 - 2012

Publications (116)

• Age 35 in SOFT: Prognostic Boundary, Treatment-Effect Modifier, or Surrogate of Clinical Risk?
  Annals of Oncology 2026 DOI: 10.1016/j.annonc.2026.10.099
  +Save
• Immunotherapy in Soft Tissue Sarcomas—An Ongoing Quest
  Cells 2026 DOI: 10.3390/cells15141297
  +Save
• Differentiating Upper Tract Urothelial Carcinoma with Synchronous or Metachronous Bladder Cancer
  Current Issues in Molecular Biology 2026 DOI: 10.3390/cimb48040345
  +Save
• Risk Factors for Disease Recurrence in Patients with HER2+ Early Breast Cancer and Implications for Therapy: A Narrative Review
  Oncology and Therapy 2026 DOI: 10.1007/s40487-025-00398-4
  +Save
• An Implementation Roadmap to Accelerate Academic Clinical Cancer Research in Portugal: A Multistakeholder Perspective
  Acta Médica Portuguesa 2026 DOI: 10.20344/amp.23479
  +Save
• Assessing the Impact of Comprehensive Genomic Profiling on Therapeutic Selection for Advanced Solid Tumors in Portugal
  Current Oncology 2026 DOI: 10.3390/curroncol33020066
  +Save
• Biomarker Profiling of Upper Tract Urothelial Carcinoma Only and with Synchronous or Metachronous Bladder Cancer
  Biomedicines 2024 DOI: 10.3390/biomedicines12092154
  +Save
• Effect of Cyclin-Dependent Kinase 4/6 Inhibitors on Circulating Cells in Patients with Metastatic Breast Cancer
  Cells 2024 DOI: 10.3390/cells13161391
  +Save
• Diagnostic delays in breast cancer among young women: An emphasis on healthcare providers
  Luís Costa, Rakesh Kumar, Cynthia Mayte Villarreal-Garza +11 more
  The Breast 2024 DOI: 10.1016/j.breast.2023.103623
  +Save
• The Evolving Pathways of the Efficacy of and Resistance to CDK4/6 Inhibitors in Breast Cancer
  Cancers 2023 DOI: 10.3390/cancers15194835
  +Save
• Breast Sarcomas, Phyllodes Tumors, and Desmoid Tumors: Turning the Magnifying Glass on Rare and Aggressive Entities
  Cancers 2023 DOI: 10.3390/cancers15153933
  +Save
• Immunotherapy around the Clock: Impact of Infusion Timing on Stage IV Melanoma Outcomes
  Cells 2023 DOI: 10.3390/cells12162068
  +Save
• Targeting Inhibitor of Apoptosis Proteins to Overcome Chemotherapy Resistance—A Marriage between Targeted Therapy and Cytotoxic Chemotherapy
  International Journal of Molecular Sciences 2023 DOI: 10.3390/ijms241713385
  +Save
• 360 Health Analysis (H360)—A Comparison of Key Performance Indicators in Breast Cancer Management across Health Institution Settings in Portugal
  Current Oncology 2023 DOI: 10.3390/curroncol30070451
  +Save
• Clinical Validation of a Size-Based Microfluidic Device for Circulating Tumor Cell Isolation and Analysis in Renal Cell Carcinoma
  International Journal of Molecular Sciences 2023 DOI: 10.3390/ijms24098404
  +Save
• Multidisciplinary Approach to Spinal Metastases and Metastatic Spinal Cord Compression—A New Integrative Flowchart for Patient Management
  Cancers 2023 DOI: 10.3390/cancers15061796
  +Save
• Radiotherapy, Chemotherapy and Immunotherapy—Current Practice and Future Perspectives for Recurrent/Metastatic Oral Cavity Squamous Cell Carcinoma
  Diagnostics 2022 DOI: 10.3390/diagnostics13010099
  +Save
• Therapeutic Potential of Deflamin against Colorectal Cancer Development and Progression
  Cancers 2022 DOI: 10.3390/cancers14246182
  +Save
• Comprehensive Genomic Profiling of Cell-Free Circulating Tumor DNA Detects Response to Ribociclib Plus Letrozole in a Patient with Metastatic Breast Cancer
  Biomolecules 2022 DOI: 10.3390/biom12121818
  +Save
• On the Relevance of Soft Tissue Sarcomas Metabolic Landscape Mapping
  International Journal of Molecular Sciences 2022 DOI: 10.3390/ijms231911430
  +Save